Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ANNX |
---|---|---|
09:32 ET | 70088 | 8.07 |
09:34 ET | 51407 | 8.15 |
09:36 ET | 75804 | 7.83 |
09:38 ET | 23969 | 7.83 |
09:39 ET | 18455 | 7.72 |
09:41 ET | 19108 | 7.7501 |
09:43 ET | 33783 | 7.8556 |
09:45 ET | 28794 | 7.91 |
09:48 ET | 41661 | 7.79 |
09:50 ET | 5205 | 7.95 |
09:52 ET | 22273 | 8.1 |
09:54 ET | 43492 | 8.12 |
09:56 ET | 11632 | 8.069 |
09:57 ET | 6817 | 8.085 |
09:59 ET | 5961 | 8.11 |
10:01 ET | 35798 | 8.19 |
10:03 ET | 10779 | 8.2004 |
10:06 ET | 25199 | 8.19 |
10:08 ET | 44470 | 8.09 |
10:10 ET | 4453 | 8 |
10:12 ET | 12592 | 8.02 |
10:14 ET | 4495 | 8.02 |
10:15 ET | 40080 | 8.005 |
10:17 ET | 1500 | 7.99 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Annexon Inc | 703.1M | -4.5x | --- |
Korro Bio Inc | 709.3M | -1.0x | --- |
Northwest Biotherapeutics Inc | 714.0M | -10.5x | --- |
Savara Inc | 670.0M | -14.3x | --- |
Mind Medicine (MindMed) Inc | 667.5M | -4.0x | --- |
Astria Therapeutics Inc | 746.7M | -5.7x | --- |
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is also evaluating ANX005 for the potential treatment of patients with Huntington’s disease (HD). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $703.1M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 90.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.16 |
EPS | $-1.78 |
Book Value | $3.20 |
P/E Ratio | -4.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.